

RHEUMATOLOGY

PAPER-III

RHM/D/18/43/III

Time: 3 hours

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. Discuss the two different types of uveitis seen in juvenile idiopathic arthritis. How do you screen children with JIA for uveitis? What are the current guidelines for management of a child with chronic anterior uveitis? 2+3+5
2. What are the various conditions that mimic scleroderma? How do you treat linear scleroderma? 7+3
3. How can you differentiate lupus flare in pregnancy from pre-eclampsia? Discuss the role of urinary biomarkers in lupus nephritis. 5+5
4. Discuss efficacy and safety of different agents used in maintenance treatment of ANCA associated vasculitis? What is the treatment of relapsed ANCA associated vasculitis? 6+4
5. Draw a diagram to explain pathogenesis of Sjogren syndrome (SS). What is the risk of lymphoma in SS and what are the risk factors for it? 5+(2+3)
6. What are the common genes implicated in pathogenesis of SLE? Describe in brief the immuno-pathogenesis of SLE? 4+6
7. Discuss the JAK-STAT pathway of cytokine signaling. List the drugs that target different JAKs and their clinical utility. 5+5
8. What are the indications of knee replacement? What are the early and late complication of total knee replacement? 5+5
9. What are checkpoint inhibitors? Discuss autoimmune rheumatic diseases associated with checkpoint inhibitor therapy for cancer. Why do these patients develop these side effects? 2+5+3
10. List the various myositis specific auto antibodies, their prevalence and clinical association. Which of these autoantibodies are associated with increased risk of malignancy? 8+2
